An Evaluation Of Respiratory Samples for Staphylococcus Resistance PatternsS (MRSA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00754273 |
Recruitment Status
:
Completed
First Posted
: September 17, 2008
Last Update Posted
: March 23, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Methicillin-resistant Staphylococcal Aureus Pneumonia | Other: etest susceptability testing |

Study Type : | Observational |
Estimated Enrollment : | 1250 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Prospective Evaluation Of Protected Alveolar Lavage (PAL) Staphylococcus Aurues Resistance Patterns |
Study Start Date : | September 2008 |
Actual Primary Completion Date : | July 2010 |
Actual Study Completion Date : | July 2010 |

Group/Cohort | Intervention/treatment |
---|---|
1
PAL samples collected for pneumonia evaluation
|
Other: etest susceptability testing
E-test methodology is performed on all MRSA samples using standardized inoculum (0.5 McFarland) for Tigecycline, Vancomycin, Teicoplanin, and Linezolid. E test is performed using heavy inoculum for Vancomycin and Teicoplanin (2.0 McFarland).
|
- Determine the prevalence of PAL hetero-VISA within MRSA isolates using vancomycin E-tests and contrast this with E-tests for teicoplanin, linezolid and tigecycline. [ Time Frame: 1 time ]
- Determine the sensitivity and specificity of automated susceptibility testing for PAL MRSA for vancomycin and alternative agents teicoplanin, linezolid and tigecycline by comparing automated sensitivity testing to E-test results. [ Time Frame: 1 time ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Isolates of MRSA from PAL samples
Exclusion Criteria:

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00754273
United States, Kentucky | |
University of Kentucky Medical Center | |
Lexington, Kentucky, United States, 40536 |
Principal Investigator: | Andrew C. Bernard, M.D. | University of Kentucky |
Responsible Party: | Andrew Bernard, M.D., University of Kentucky Medical Center |
ClinicalTrials.gov Identifier: | NCT00754273 History of Changes |
Other Study ID Numbers: |
07-0775-P6H |
First Posted: | September 17, 2008 Key Record Dates |
Last Update Posted: | March 23, 2011 |
Last Verified: | March 2011 |
Additional relevant MeSH terms:
Pneumonia Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections |